United Therapeutics Corporation (BMV:UTHR)

Market Cap	401.52B +47.1%
Revenue (ttm)	57.14B +5.9%
Net Income	23.21B +6.3%
EPS	487.93 +7.8%
Shares Out	n/a
PE Ratio	17.30
Forward PE	16.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6
Open	9,535.62
Previous Close	n/a
Day's Range	9,535.62 - 9,535.62
52-Week Range	5,672.39 - 9,884.33
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 29, 2026

About United Therapeutics

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 1,400
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: UTHR

Financial Performance

In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.

Financial numbers in USD